Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 cendakimab induction and maintenance study in eosinophilic esophagitis
2020-004336-16Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Feb 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in eosinophilic esophagitis (EoE) comparing Cendakimab with Placebo (2 arms). Primary endpoint: Mean change in dysphagia days. Started Feb 2021; status: completed.
02
Drugs
cendakimab
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on 2020-004336-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004336-16.